The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with lanadelumab under the National Health Act 1953, section 85 for patients aged 12 years or older with hereditary angioedema (HAE) type 1 or 2.
Patients must be eligible for the PBS and meet the relevant restriction criteria.
The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing lanadelumab.
To be eligible for PBS-subsidised treatment with lanadelumab, patients must be treated by a clinical immunologist or a specialist allergist.
Applying for initial treatment
Apply for initial authority approval to prescribe PBS-subsidised lanadelumab for patients commencing with no previous treatment with C1-esterase inhibitor (C1-INH) or who are commencing from National Blood Authority funded C1-INH to treat hereditary angioedema type 1 or 2 in writing and either:
All written applications must include the completed:
- authority prescription form or forms
- Hereditary angioedema type 1 or 2 - lanadelumab - initial authority application form
- relevant attachments.
Applying for continuing treatment
Applications for continuing authority approval to prescribe PBS-subsidised lanadelumab to treat hereditary angioedema type 1 or 2 can be made either:
- in real time using the Online PBS Authorities system
- by calling the PBS Complex Drugs Programs enquiry line.
Call the PBS Complex Drugs Programs enquiry line for further information.